Table 1 Clinical trials using BMMNCs and PBMNCs for CLI patients
From: Therapeutic strategies for cell-based neovascularization in critical limb ischemia
Author | Year | Cell type | Target disease | Delivery | Study population | Outcome | Follow-up | References |
|---|---|---|---|---|---|---|---|---|
Esato et al. | 2002 | BMMNC | CLI | IM | 8 | ↑Symptom, ↑thermography, complete ulcer healing; 2/3 (67%) major amputation rates; 0 | Not determined | [20] |
Tateishi-Yuyama et al. | 2002 | BMMNC and PBMNC | CLI | IM | 45 | ↑Symptom, ↑ABI, ↑TcPO2, complete ulcer healing; 6/10 (60%) major amputation rates; not shown | 4 and 24 weeks | [25] |
Huang et al. | 2005 | PBMNC | CLI | IM | 28 | ↑Symptom, ↑ABI, ↑LDP, complete ulcer healing; 14/18 (78%) major amputation rates; 0 | 3 months | [88] |
Lenk et al. | 2005 | PBMNC | CLI | IA | 7 | ↑Symptom, ↑ABI, ↑TcPO2, complete ulcer healing; not shown major amputation rates; 0 | 20 weeks | [89] |
Miyamoto et al. | 2006 | BMMNC | CLI | IM | 8 | ↑Symptom, no ∆ ABI, complete ulcer healing; 7/8 (88%) major amputation rates; 0 | 684 days | [81] |
Durdu et al. | 2006 | BMMNC | CLI | IM | 28 | ↑Symptom, ↑ABI, ↑LDP, complete ulcer healing; 15/18 (83%) major amputation rates; 0 | 16.6 months | [79] |
Arai et al. | 2006 | BMMNC | CLI | IM | 39 | ↑Symptom, ↑ABI, ↑TcPO2, complete ulcer healing; 3/8 (38%) major amputation rates; not shown | 1 months | [90] |
Kawamoto et al. | 2009 | PBMNC (CD34+) | CLI | IM | 17 | ↑Symptom, ↑TBI, ↑TcPO2, no ∆ ABI, complete ulcer healing; not shown major amputation rates; 0 | 3 months | [91] |
Prochazka et al. | 2010 | BMC | CLI | IM | 96 | ↑Symptom, ↑ABI, ↑LDP, ↑SPP, no ∆ TcPO2, complete ulcer healing; 33/42 (79%) major amputation rates; 9/42 (21%) | 4 months | [92] |
Murphy et al. | 2011 | BMMNC | CLI | IM | 29 | ↑Symptom, ↑FTP, ↑TBI, complete ulcer healing; 3/9 (33%) major amputation rates; 4/29 (14%) | 12 months | [93] |
Walter et al. | 2011 | BMMNC | CLI | IA | 40 | ↑Symptom, no ∆ ABI, no ∆ TcPO2, complete ulcer healing; 3/15 (20%) major amputation rates; 3/19 (16%) | 3 months | [78] |
Losordo et al. | 2012 | PBMNC (CD34+) | CLI | IM | 28 | No ∆ symptom, no ∆ ABI, no ∆ TBI, complete ulcer healing; 2/5 (40%) major amputation rates; 5/16 (31%) | 12 months | [94] |
Tanaka et al. | 2014 | PBMNC (CD34+) | CLI | IM | 5 | ↑Symptom, ↑SPP, ↑TcPO2, no ∆ ABI, complete ulcer healing; 2/5 (40%) major amputation rates; 0 | 5 months | [95] |
Teraa et al. | 2015 | BMMNC | CLI | IA | 160 | ↑Symptom, ↑ABI, ↑TcPO2, complete ulcer healing; 19/51 (37%) major amputation rates; 21/81 (26%) | 9 months | [96] |